Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
BMC Endocr Disord ; 24(1): 20, 2024 Feb 08.
Article in English | MEDLINE | ID: mdl-38326790

ABSTRACT

BACKGROUND: Lymphocytic hypophysitis is a rare autoimmune condition that usually presents during pregnancy and causes inflammation of the pituitary gland. Although the pathophysiology is not well understood, it often presents with headaches, visual disturbances, and symptoms of hypopituitarism. However, not all cases may present with hypopituitarism which can make this rare disease with an incidence of ~ 1 in 9 million much more difficult to diagnose. CASE PRESENTATION: We present a 35-year-old G4P4 woman with progressive vision loss and intermittent frontal headaches during her first trimester through 2 months postpartum. She presented with no symptoms of hypopituitarism and her hormone panel only showed elevated prolactin, possibly due to her breastfeeding. She was treated with a right pterional craniotomy with decompression of both optic nerves, partial resection of the suprasellar mass, and glucocorticoid therapy for headaches and visual disturbances. CONCLUSION: This case is notable for a presentation of lymphocytic hypophysitis without symptoms of hypopituitarism. This is important for outpatient providers to be aware of, especially those that care for pregnant patients so that unfavorable outcomes can be avoided.


Subject(s)
Autoimmune Hypophysitis , Hypopituitarism , Pituitary Diseases , Pituitary Neoplasms , Humans , Pregnancy , Female , Adult , Pituitary Neoplasms/complications , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/surgery , Autoimmune Hypophysitis/diagnosis , Autoimmune Hypophysitis/complications , Pituitary Diseases/diagnosis , Pituitary Diseases/complications , Hypopituitarism/diagnosis , Hypopituitarism/etiology , Pituitary Hormones , Headache/etiology , Headache/complications , Magnetic Resonance Imaging
2.
Can J Physiol Pharmacol ; 100(3): 210-219, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34910610

ABSTRACT

Our current investigation comprises the synthesis and pharmacological impact of bromelain copper nanoparticles (BrCuNP) against diabetes mellitus (DM) and associated ischemia/reperfusion (I/R) - induced myocardial infarction. Bromelain is a proteolytic enzyme obtained from Ananas comosus L. Merr., which has blood platelet aggregation inhibiting and arterial thrombolytic potential. Moreover, copper is well-known to facilitate glucose metabolism and strengthen cardiac muscle and antioxidant activity; although, chronic or long-term exposure to high doses of copper may lead to copperiedus. To restrict these potential hazards, we synthesized herbal nano-formulation which convincingly indicated the improved primordial therapeutic potential of copper by reformulating the treatment carrier with bromelain, resulting in facile synthesis of BrCuNP. DM was induced by administration of double cycle repetitive dose of low dose streptozotocin (20 mg/kg, i.p.) in high-fat diet- fed animals. DM and associated myocardial I/R injury were estimated by increased serum levels of total cholesterol, low-density lipoprotein, very low-density lipoprotein, lactate dehydrogenase, creatine kinase myocardial band, cardiac troponin, thiobarbituric acid reactive substances, tumor necrosis factor α, interleukin 6, and reduced serum level of high-density lipoprotein and nitrite/nitrate concentration. However, treatment with BrCuNP ameliorates various serum biomarkers by approving cardioprotective potential against DM- and I/R-associated injury. Furthermore, upturn of histopathological changes were observed in cardiac tissue of BrCuNP-treated rats in comparison to disease models.


Subject(s)
Bromelains/chemical synthesis , Bromelains/therapeutic use , Copper/chemistry , Copper/therapeutic use , Diabetes Complications/complications , Metal Nanoparticles/chemistry , Metal Nanoparticles/therapeutic use , Myocardial Infarction/drug therapy , Myocardial Infarction/etiology , Myocardial Reperfusion Injury/complications , Animals , Bromelains/pharmacology , Copper/pharmacology , Disease Models, Animal , Female , Rats, Wistar
3.
Thyroid ; 24(10): 1479-87, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24811481

ABSTRACT

BACKGROUND: Molecular testing for oncogenic gene mutations and chromosomal rearrangements plays a growing role in the optimal management of thyroid nodules, yet lacks standardized testing modalities and systematic validation data. Our objective was to assess the performance of molecular cytology on preoperative thyroid nodule fine-needle aspirates (FNAs) across a broad range of variables, including independent collection sites, clinical practices, and anatomic pathology interpretations. METHODS: Single-pass FNAs were prospectively collected from 806 nodules 1 cm or larger by ultrasonography at five independent sites across the United States. Specimens were shipped in a nucleic acid stabilization solution and tested at a centralized clinical laboratory. Seventeen genetic alterations (BRAF, KRAS, HRAS, and NRAS mutations, PAX8-PPARG and RET-PTC rearrangements) were evaluated by multiplex polymerase chain reaction and liquid bead array cytometry in 769 FNAs that met inclusion criteria. Cytology, histology, and clinical care followed local procedures and practices. All results were double-blinded. RESULTS: Thirty-two specimens (4.2%) failed to yield sufficient nucleic acid to generate molecular data. A single genetic alteration was detected in 80% of cytology malignant cases, 21% of indeterminate, 7.8% of nondiagnostic, and 3.5% of benign cases. Among 109 nodules with surgical histology reference standard, oncogenic mutations were present in 50% of malignant nodules missed by cytology. There were 14 cancers not identified by cytology or molecular tests, including 5 carcinomas with histologic sizes less than 1 cm (3 multifocal) and 8 noninvasive follicular variants of papillary carcinoma (4 encapsulated). No mutations were detected in 89% of the nodules benign by histopathology with 6 false-positive molecular results in 5 adenomas (2-5.5 cm) and 1 cystic nodule with an incidental papillary microcarcinoma (0.15 cm). The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall. CONCLUSIONS: Centralized and standardized molecular testing for genetic alterations associated with a high risk of malignancy efficiently complements the local cytopathologic diagnosis of thyroid nodule aspirates in the clinical setting. Actionable molecular cytology can improve the personalized surgical and medical management of patients with thyroid cancers, facilitating one-stage total thyroidectomy and reducing the number of unnecessary diagnostic surgeries.


Subject(s)
Biomarkers, Tumor/genetics , Biopsy, Fine-Needle/standards , DNA Mutational Analysis/standards , Mutation , Oncogenes , Pathology, Clinical/standards , Thyroid Neoplasms/diagnosis , Thyroid Nodule/diagnosis , Double-Blind Method , Genetic Predisposition to Disease , Guideline Adherence , Humans , Organizational Objectives , Pathology, Clinical/methods , Pathology, Clinical/organization & administration , Phenotype , Practice Guidelines as Topic , Predictive Value of Tests , Prognosis , Prospective Studies , Reproducibility of Results , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Thyroid Nodule/genetics , Thyroid Nodule/pathology , Tumor Burden , United States , Workflow
4.
Pancreas ; 42(6): 912-23, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23851429

ABSTRACT

Pancreatic neuroendocrine tumors (PNETs), also known as islet cell tumors, are mostly indolent neoplasms that probably arise from a network of endocrine cells that includes islet cells and pluripotent precursors in the pancreatic ductal epithelium. The incidence and prevalence of PNETs continue to rise in recent years because of more sensitive detection. The molecular pathogenesis, early detection, molecular predictors of tumor behavior, and targeted drug therapy of PNETs are not well understood and require additional basic and translational research. The rarity and indolent nature of these tumors, difficulty of access to appropriate patient tissue samples, and varying histopathology and secreted hormones pose particular challenges to PNET researchers. Animal models and cell lines are indispensable tools for investigating the pathogenesis, pathophysiology, mechanisms for tumor invasion and metastasis, and therapeutics of PNETs. This review summarizes currently available animal models and cell lines of PNETs, which have provided valuable insights into the pathogenesis and natural history of human PNETs. In the future, animal models and cell lines of PNETs should also be used to study early tumor detection and molecular predictors of tumor behavior and to test the responses to, and mechanisms for, novel targeted drug therapies.


Subject(s)
Disease Models, Animal , Neuroendocrine Tumors/pathology , Pancreatic Neoplasms/pathology , Animals , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Mice, Knockout , Mice, Transgenic , Molecular Targeted Therapy , Neuroendocrine Tumors/genetics , Neuroendocrine Tumors/therapy , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/therapy
5.
Int J Cardiol ; 145(2): 266-267, 2010 Nov 19.
Article in English | MEDLINE | ID: mdl-19840890

ABSTRACT

The recent death of a popular politician in India was followed by a spate of sudden deaths. In this letter, we analyze the deaths as reported in newspapers, and try to arrive at a reason for this strange phenomenon.


Subject(s)
Accidents, Aviation , Death, Sudden/epidemiology , Famous Persons , Politics , Accidents, Aviation/psychology , Adult , Aged , Cause of Death/trends , Death, Sudden/etiology , Female , Humans , India/epidemiology , Male , Middle Aged , Risk Factors , Young Adult
7.
Clin Infect Dis ; 43(8): 1085-6, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16983628
SELECTION OF CITATIONS
SEARCH DETAIL
...